Similar articles

• Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing.

  Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, Walsh CE. Chao H, et al. Nat Med. 2003 Aug;9(8):1015-9. doi: 10.1038/nm900. Epub 2003 Jul 6. Nat Med. 2003. PMID: 12847523
• Animal testing of retroviral-mediated gene therapy for factor VIII deficiency.

  Greengard JS, Jolly DJ. Greengard JS, et al. Thromb Haemost. 1999 Aug;82(2):555-61. Thromb Haemost. 1999. PMID: 10605751 Review. No abstract available.
• Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.

  Liu L, Mah C, Fletcher BS. Liu L, et al. Mol Ther. 2006 May;13(5):1006-15. doi: 10.1016/j.ymthe.2005.11.021. Epub 2006 Feb 7. Mol Ther. 2006. PMID: 16464640
• Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A.

  Hrachovinová I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD. Hrachovinová I, et al. Nat Med. 2003 Aug;9(8):1020-5. doi: 10.1038/nm899. Epub 2003 Jul 13. Nat Med. 2003. PMID: 12858167
• Preclinical animal models for hemophilia gene therapy: predictive value and limitations.

  Rawle FE, Lillicrap D. Rawle FE, et al. Semin Thromb Hemost. 2004 Apr;30(2):205-13. doi: 10.1055/s-2004-825634. Semin Thromb Hemost. 2004. PMID: 15118932 Review.